Monoclonal antibodies such as tocilizumab and sarilumab, which inhibit IL-6 receptor signaling, markedly reduce circulating CRP levels and have shown cognitive and fatigue benefits in inflammatory disorders including rheumatoid arthritis and post-COVID syndromes. Here, CRP is linked to rheumatoid arthritis.